FDA rejects Teva’s high-potency biosimilar of Humira again — After a record run, fewer biotechs are going public— Sarepta shares drop as report says FDA almost rejected under-review gene therapy -- See more on our front page news http://bit.ly/w28kSd #tevapharma #fda #humira #abbvie #biosimilars #ipos #genetherapy #sarepta #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
#tevapharma #FdA #humira #abbvie #biosimilars #ipos #genetherapy #sarepta #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
Teva names ex-Sandoz exec Richard Francis to replace CEO Schultz
https://pharmaphorum.com/news/teva-names-ex-sandoz-exec-richard-francis-to-replace-ceo-schultz